Scinai Immunotherapeutics Finalizes Acquisition of CDMO Arm for Nominal Consideration, Reports Pro Forma Financials
SCNI sits 20% above its 52-week low of $0.455.
Summary
Scinai Immunotherapeutics Ltd. has filed pro forma financial statements detailing its acquisition of Scinai Biopharma Service Ltd. for nominal consideration, which includes a capital injection and results in a bargain purchase gain, significantly expanding its CDMO capabilities.
Key Events · M&A and Partnerships · SCNI
-
Acquisition of CDMO Business Finalized
Scinai Immunotherapeutics completed the acquisition of Scinai Biopharma Service Ltd. (formerly Recipharm Israel Ltd.), a CDMO (Contract Development and Manufacturing Organization) business, for a nominal consideration of EUR 1.
-
Favorable Acquisition Terms
The transaction included the acquisition of an approximately EUR 13.9 million shareholder loan for nominal consideration and a EUR 2 million capital injection from the seller, Recipharm AB, prior to closing.
-
Bargain Purchase Gain Recognized
The pro forma financial information reflects a bargain purchase gain, attributed to the seller's strategic realignment and regional security conditions, allowing Scinai to acquire the assets at a significant discount.
-
Pro Forma Financial Impact
The unaudited pro forma consolidated financials for 2025 show a combined net loss of approximately $10.96 million, reflecting the integration of the acquired entity which previously had a going concern warning and accumulated deficits.
Analysis · SCNI · Life Sciences
This filing provides the financial details and pro forma impact of Scinai Immunotherapeutics' acquisition of Scinai Biopharma Service Ltd. (formerly Recipharm Israel Ltd.), a CDMO business. The acquisition was completed for a nominal EUR 1, with Scinai also acquiring a significant shareholder loan for nominal consideration and receiving a EUR 2 million capital injection from the seller. This favorable transaction structure led to the recognition of a bargain purchase gain. While the acquired entity had a history of losses and a going concern warning, this strategic move significantly expands Scinai's operational scope into contract development and manufacturing. Investors should note the substantial pro forma combined net loss of approximately $10.96 million for 2025, indicating ongoing financial challenges for the enlarged entity, despite the advantageous acquisition terms.
At the time of this filing, SCNI was trading at $0.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9M. The 52-week trading range was $0.45 to $6.18. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.